GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Aprinoia Therapeutics Inc (NAS:APRI) » Definitions » Net Current Asset Value

Aprinoia Therapeutics (Aprinoia Therapeutics) Net Current Asset Value : $-3.12 (As of Jun. 2023)


View and export this data going back to 2050. Start your Free Trial

What is Aprinoia Therapeutics Net Current Asset Value?

In calculating the Net Current Asset Value (NCAV), Benjamin Graham means a company's current assets (such as cash, marketable securities, and inventories) minus its total liabilities (including preferred stock, minority interest, and long-term debt).

Aprinoia Therapeutics's net current asset value per share for the quarter that ended in Jun. 2023 was $-3.12.

The historical rank and industry rank for Aprinoia Therapeutics's Net Current Asset Value or its related term are showing as below:

APRI's Price-to-Net-Current-Asset-Value is not ranked *
in the Biotechnology industry.
Industry Median: 3.84
* Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.

Aprinoia Therapeutics Net Current Asset Value Historical Data

The historical data trend for Aprinoia Therapeutics's Net Current Asset Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aprinoia Therapeutics Net Current Asset Value Chart

Aprinoia Therapeutics Annual Data
Trend Dec21 Dec22
Net Current Asset Value
-1.84 -2.85

Aprinoia Therapeutics Semi-Annual Data
Dec21 Jun22 Dec22 Jun23
Net Current Asset Value -1.84 - -2.85 -3.12

Competitive Comparison of Aprinoia Therapeutics's Net Current Asset Value

For the Biotechnology subindustry, Aprinoia Therapeutics's Price-to-Net-Current-Asset-Value, along with its competitors' market caps and Price-to-Net-Current-Asset-Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Aprinoia Therapeutics's Price-to-Net-Current-Asset-Value Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Aprinoia Therapeutics's Price-to-Net-Current-Asset-Value distribution charts can be found below:

* The bar in red indicates where Aprinoia Therapeutics's Price-to-Net-Current-Asset-Value falls into.



Aprinoia Therapeutics Net Current Asset Value Calculation

Aprinoia Therapeutics's Net Current Asset Value (NCAV) per share for the fiscal year that ended in Dec. 2022 is calculated as

Net Current Asset Value Per Share(A: Dec. 2022 )
=(Total Current Assets-Total Liabilities-Minority Interest-Preferred Stock)/Shares Outstanding (EOP)
=(1.811-81.093-0-0)/27.829
=-2.85

Aprinoia Therapeutics's Net Current Asset Value (NCAV) per share for the quarter that ended in Jun. 2023 is calculated as

Net Current Asset Value Per Share(Q: Jun. 2023 )
=(Total Current Assets-Total Liabilities-Minority Interest-Preferred Stock)/Shares Outstanding (EOP)
=(9.553-96.408-0-0)/27.829
=-3.12

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Aprinoia Therapeutics  (NAS:APRI) Net Current Asset Value Explanation

Benjamin Graham first discussed net current asset value (NCAV) in the 1934 edition of "Security Analysis", which he coauthored with David Dodd. In the book, (net) current asset value is defined as:" current assets alone, minus all liabilities and claims ahead of the issue."

The common definition of NCAV is: NCAV = current assets – [total liabilities + minority interest + preferred stock]

Net current assets exclude not only the intangible assets but also the fixed and miscellaneous assets. In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. In "Security Analysis", preferred stock is dubbed "an imperfect creditorship position" that is best placed on the balance sheet alongside funded debt.

One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham’s strategy produced similar results.

Benjamin Graham looked for companies whose market values were less than two-thirds of their Net-Net Working Capital. They are collected under our Net-Net screener.


Aprinoia Therapeutics Net Current Asset Value Related Terms

Thank you for viewing the detailed overview of Aprinoia Therapeutics's Net Current Asset Value provided by GuruFocus.com. Please click on the following links to see related term pages.


Aprinoia Therapeutics (Aprinoia Therapeutics) Business Description

Comparable Companies
Traded in Other Exchanges
N/A
Address
Website
Aprinoia Therapeutics Inc is a clinical-stage biotechnology company. It is engaged in protecting patients' brain health and changing clinical outcomes for a broad range of neurodegenerative diseases by developing novel, highly sensitive and selective diagnostic tools and novel therapeutics. Neurodegenerative diseases are relentless and largely fatal, resulting from progressive loss of nerve cells in the brain and, depending on the specific disorders, can affect a broad range of cognitive, behavioral, and motor functions, such as memory, thinking, speaking, walking, and breathing. It is developing several different diagnostic and therapeutic platforms such as abnormal protein aggregates of tau and alpha synuclein ("?-Syn") that are toxic to brain cells.

Aprinoia Therapeutics (Aprinoia Therapeutics) Headlines

No Headlines